Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (2 issues)
Up 5.61% on 1.93x volume with RSI at 70.2, above every moving average and 4.1% from its high; the $567.81 target across 32 analysts leaves 8.4% — healthy trend, extended entry.
Up 2.49% with RSI healthy at 59.6, above the 50-day at $473.16 and 200-day at $454.68; it moved with the biopharma complex but lacks a company-specific catalyst. Sidelines.